Skip to main content
SpringerLink
Log in

Organ Directed Toxicities of Anticancer Drugs

Proceedings of the First International Symposium on the Organ Directed Toxicities of the Anticancer Drugs Burlington, Vermont, USA-June 4–6, 1987

  • Conference proceedings
  • © 1988

Overview

Editors:
  1. Miles P. Hacker

    1. Vermont Regional Cancer Center, Burlington, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. John S. Lazo

    1. Yale University School of Medicine, New Haven, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Thomas R. Tritton

    1. Vermont Regional Cancer Center, Burlington, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Oncology (DION, volume 53)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (20 papers)

  1. Front Matter

    Pages i-xii
    Download chapter PDF

  2. Keynote Address

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. The Irrelevant Toxicities of Anticancer Drugs

      • I. H. Krakoff
      Pages 3-10

  3. Anthracycline Induced Cardiotoxicity

    1. Front Matter

      Pages 11-11
      Download chapter PDF

    2. Overview

      • T. R. Tritton
      Pages 13-16

    3. Role of Iron in Anthracycline Action

      • C. E. Myers
      Pages 17-30

    4. Role of Reactive Oxygen Production in Doxorubicin Cardiac Toxicity

      • J. H. Doroshow
      Pages 31-40

    5. Adriamycin Cardiac Toxicity — An Assessment of Approaches to Cardiac Monitoring and Cardioprotection

      • R. S. Benjamin, S. P. Chawla, M. S. Ewer, G. N. Hortobagyi, B. Mackay, S. S. Legha et al.
      Pages 41-55

    6. Pretreatment with ICRF-187 Protects Against the Chronic Cardiac Toxicity Produced by Very Large Cumulative Doses of Doxorubicin in Beagle Dogs

      • V. J. Ferrans, E. H. Herman, R. L. Hamlin
      Pages 56-63

    7. A Trial of ICRF-187 to Selectively Protect Against Chronic Adriamycin Cardiac Toxicity: Rationale and Preliminary Results of a Clinical Trial

      • J. L. Speyer, M. D. Green, C. Ward, J. Sanger, E. Kramer, M. Rey et al.
      Pages 64-73

  4. Bleomycin Induced Pulmonary Toxicity

    1. Front Matter

      Pages 75-75
      Download chapter PDF

    2. Overview

      • J. S. Lazo
      Pages 77-78

    3. Base Propenals and the Toxicity of Bleomycin

      • A. P. Grollman
      Pages 79-90

    4. Bleomycin Induced Lung Injury

      • A. F. Tryka
      Pages 91-106

    5. Immunoregulation of Growth Factor Release in Bleomycin Induced Lung Disease

      • J. Kelley, M. Absher, E. J. Kovacs
      Pages 107-117

    6. Pulmonary Toxicity of Anticancer Drugs: Alterations in Endothelial Cell Function

      • J. D. Catravas
      Pages 118-127

    7. Pulmonary Metabolic Inactivation of Bleomycin and Protection from Drug-Induced Lung Injury

      • J. S. Lazo, J. E. Mignano, S. M. Sebti
      Pages 128-139

    8. Biochemical and Molecular Bases of Bleomycin-Induced Pulmonary Fibrosis: Glucocorticoid Intervention

      • K. R. Cutroneo, D. Cockayne, K. M. Sterling Jr.
      Pages 140-151

  5. Platinum Induced Nephrotoxicity

    1. Front Matter

      Pages 153-153
      Download chapter PDF

    2. Overview

      • M. P. Hacker
      Pages 155-158
Back to top

Keywords

About this book

The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif­ ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in­ tervention. Much of this toxicity, such as damage to the bone marrow, gastroin­ testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre­ dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs.

Editors and Affiliations

  • Vermont Regional Cancer Center, Burlington, USA

    Miles P. Hacker, Thomas R. Tritton

  • Yale University School of Medicine, New Haven, USA

    John S. Lazo

Bibliographic Information

  • Book Title: Organ Directed Toxicities of Anticancer Drugs

  • Book Subtitle: Proceedings of the First International Symposium on the Organ Directed Toxicities of the Anticancer Drugs Burlington, Vermont, USA-June 4–6, 1987

  • Editors: Miles P. Hacker, John S. Lazo, Thomas R. Tritton

  • Series Title: Developments in Oncology

  • DOI: https://doi.org/10.1007/978-1-4613-2023-4

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishing, Boston 1988

  • Hardcover ISBN: 978-0-89838-356-0Published: 31 January 1988

  • Softcover ISBN: 978-1-4612-9205-0Published: 24 November 2011

  • eBook ISBN: 978-1-4613-2023-4Published: 06 December 2012

  • Edition Number: 1

  • Number of Pages: XII, 254

  • Topics: Oncology, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation